

A peer-reviewed version of this preprint was published in PeerJ on 13 June 2016.

[View the peer-reviewed version](https://doi.org/10.7717/peerj-cs.67) (peerj.com/articles/cs-67), which is the preferred citable publication unless you specifically need to cite this preprint.

Anaya J. 2016. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Computer Science 2:e67
<https://doi.org/10.7717/peerj-cs.67>

OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs

Jordan Anaya

OncoLnc is a tool for interactively exploring survival correlations, and for downloading clinical data coupled to expression data for mRNAs, miRNAs, or lncRNAs. OncoLnc contains survival data for 8,647 patients from 21 cancer studies performed by The Cancer Genome Atlas (TCGA), along with RNA-SEQ expression for mRNAs and miRNAs from TCGA, and lncRNA expression from MiTranscriptome beta. Storing this data gives users the ability to separate patients by gene expression, and then create publication-quality Kaplan-Meier plots or download the data for further analyses. OncoLnc also stores precomputed survival analyses, allowing users to quickly explore survival correlations for up to 21 cancers in a single click. This resource allows researchers studying a specific gene to quickly investigate if it may have a role in cancer, and the supporting data allows researchers studying a specific cancer to identify the mRNAs, miRNAs, and lncRNAs most correlated with survival, and researchers looking for a novel lncRNA involved with cancer lists of potential candidates. OncoLnc is available at <http://www.oncolnc.org>

OncoLnc: Linking TCGA survival data to mRNAs, miRNAs, and lncRNAs

Jordan Anaya¹

¹omnesres.com, email: omnesresnetwork@gmail.com, twitter: @omnesresnetwork

Corresponding Author:

Jordan Anaya

Charlottesville, VA, US

email address: omnesresnetwork@gmail.com

Abstract

OncoLnc is a tool for interactively exploring survival correlations, and for downloading clinical data coupled to expression data for mRNAs, miRNAs, or lncRNAs. OncoLnc contains survival data for 8,647 patients from 21 cancer studies performed by The Cancer Genome Atlas (TCGA), along with RNA-SEQ expression for mRNAs and miRNAs from TCGA, and lncRNA expression from MiTranscriptome beta. Storing this data gives users the ability to separate patients by gene expression, and then create publication-quality Kaplan-Meier plots or download the data for further analyses. OncoLnc also stores precomputed survival analyses, allowing users to quickly explore survival correlations for up to 21 cancers in a single click. This resource allows researchers studying a specific gene to quickly investigate if it may have a role in cancer, and the supporting data allows researchers studying a specific cancer to identify the mRNAs, miRNAs, and lncRNAs most correlated with survival, and researchers looking for a novel lncRNA involved with cancer lists of potential candidates. OncoLnc is available at <http://www.oncolnc.org>.

Main article text

Introduction

The Cancer Genome Atlas (TCGA) provides researchers with unprecedented amounts of molecular data along with clinical and histopathological information (<http://cancergenome.nih.gov/>). This data set has not only led to increases in our understanding of cancer (Ciriello et al. 2013; Hoadley et al. 2014), but its scale has also allowed for previously impossible projects such as a comprehensive cataloguing of the human transcriptome (Han et al. 2014; Iyer et al. 2015). However, the size and complexity of this unique data set makes it difficult for cancer researchers to access and fully utilize.

Multiple resources exist to help researchers download or explore TCGA data (Cerami et al. 2012; Gyorffy et al. 2013; Koch et al. 2015). Despite this, there is no simple tool that lets users explore the correlation of a gene's expression to survival in multiple cancers at once, provides users the ability to divide patients into any high expressing and low expressing groups for Kaplan-Meier analysis, allows for simple download of the survival data coupled to expression data, and uses modern gene definitions.

In addition, although the role of long noncoding RNAs (lncRNAs) in cancer is beginning to be appreciated (Yarmishyn & Kurochkin 2015), the Tier 3 TCGA mRNA files contain expression data for only the limited number of lncRNAs that were known at the initiation of the TCGA project. As a result, tools for exploring TCGA data will not contain many lncRNAs currently being studied. Although a platform has already been developed to fill this gap (Li et al. 2015), to help the scientific community study lncRNAs OncoLnc incorporates analyses and data for

61 MiTranscriptome beta lncRNAs, <http://mitranscriptome.org/>, in addition to Tier 3 TCGA
62 mRNAs and miRNAs.

63 **Materials and methods**

64 **Code, files, and software**

65 All of the code necessary to reproduce Tables 1, 2, 3, S1, S2, and S3, and therefore the data in
66 OncoLnc, along with a limited amount of raw data and intermediate files is located at
67 https://github.com/OmnesRes/onco_lnc. The rest of the raw data can be downloaded from
68 <https://tcga-data.nci.nih.gov/tcga/> and <http://mitranscriptome.org/>. This code was run with
69 Python 2.7.5, NumPy 1.7.1, and rpy2 2.5.6, and can require upwards of 6GB of RAM. OncoLnc
70 runs on Django 1.8.2, Python 2.7, matplotlib 1.2.1, NumPy 1.7.1, rpy2 2.5.6, uses the SQLite3
71 database engine, and utilizes Bootstrap CSS and JavaScript, and Font Awesome icons.

72 **Cox models**

73 The multivariate model run for each cancer and each data type is listed at the top of Tables S1,
74 S2, and S3, and the code for running all of the Cox regressions is present in the GitHub
75 repository. In general only primary solid tumors were included in analyses, and this is
76 implemented by only using samples with "01" in the patient barcode. The exceptions are
77 LAML, which is a blood derived cancer, and therefore has the designation "03", and SKCM,
78 which contains primarily metastatic tumors, and therefore designations "01" and "06" were
79 allowed for SKCM analyses. It is possible for a patient to have more than one sequencing file,
80 and in these cases the counts were averaged. The TCGA data was downloaded on January 5th
81 and 6th, 2016, and miRBase version 21 was used. More info can be found in the GitHub
82 repository and in the text below.

83 **Results**

84 **Overview of OncoLnc**

85 OncoLnc stores over 400,000 analyses, which includes Cox regression results as well as mean
86 and median expression of each gene. For the Cox regression results, in addition to p-values,
87 OncoLnc stores the rank of the correlation. Different cancers contain very different p-value
88 distributions (Anaya et al. 2016; Yang et al. 2014), and it is unclear what causes this difference.
89 As a result, using one p-value cutoff across cancers is not possible, and the rank of the
90 correlation is a simple way to measure the relative strength of the correlation. The rank is
91 calculated per cancer, per data type. Tables 1-3 contain information about how many genes there
92 are for each cancer and each data type.

93 The mRNA and miRNA identifiers used by TCGA are out of date, and the identifiers in
94 OncoLnc have been manually curated using NCBI Gene: <http://www.ncbi.nlm.nih.gov/gene>, and

recent miRBase definitions: <http://www.mirbase.org/>. Over 2,000 mRNA symbols were updated, and these are listed in Table S4. Genes which have had their Entrez Gene ID removed from NCBI Gene, or could not be confidently mapped to a single identifier, are not included in OncoLnc but are still included in Table S1.

Using OncoLnc is very straightforward. The preferred method of using OncoLnc is to submit a gene at the home page, and this submission is not case sensitive. If a user submits a gene not in the database they will be notified and provided with links to all the possible gene names and IDs. Submission of a valid gene identifier will return correlation results for up to 21 cancers for mRNAs and miRNAs, or 18 cancers for MiTranscriptome beta lncRNAs (Fig. 1). If a gene does not meet the expression cutoff for the analysis, it will not be present in the database, and therefore a user may receive less than the maximum possible number of results. For users using OncoLnc on smaller devices, it is possible to perform a single cancer search. The link for this search is on the home page, and the user must submit the TCGA cancer abbreviation along with the gene of interest.

At the results page is a link to perform a Kaplan-Meier analysis for each cancer (Fig. 1). The user will be asked how they would like to divide the patients. Patients can be split into any non-overlapping upper and lower slices, for example upper 25 percent and lower 25 percent. Upon submission users will be presented with a PNG Kaplan-Meier plot, a logrank p-value for the analysis, and text boxes with the data that was plotted (Fig. 2). If a user simply wants all the data for that cancer and that gene, the user can submit 100 for "Lower Percentile", and 0 for "Upper Percentile".

Users then have the option to either go to a PDF of the Kaplan-Meier plot, or download a CSV file of the data plotted. In both cases the file name will be the cancer, gene ID, lower percentile, upper percentile, separated by underscores. Gene ID had to be used instead of gene name because there are multiple HUGO gene symbol conflicts between TCGA Tier 3 mRNAs and MiTranscriptome beta, as well as between TCGA mRNA HUGO gene symbols and updated mRNA HUGO gene symbols. In the case that a user performs a search for a name with a conflict, OncoLnc presents a warning message and instructs the user how to proceed.

mRNAs

Table 1 contains information about the patients for each Tier 3 mRNA study included in OncoLnc, and how many gene analyses are present in OncoLnc for each study. Tier 3 RNASeqV2 was used for all 21 cancers, and expression was taken from the "rsem.genes.normalized_results" files. As a result, the expression data in OncoLnc for Tier 3 mRNAs is in normalized RSEM values. Table 1 contains different numbers of genes for the different cancers because an expression cutoff was used to determine if a gene would be included in the analysis. For mRNAs this cutoff was a median expression greater than 1 RSEM, and less than a fourth of the patients with an expression of 0.

The results of every Tier 3 mRNA Cox regression performed are included in Table S1. The Tier 3 expression files contain both a HUGO gene symbol and Entrez Gene ID for each gene, but these IDs and gene symbols are not current. To update the gene symbols I downloaded every human gene from NCBI Gene, and updated any symbol for which the Entrez Gene ID was still current. For genes that had deleted or changed Entrez Gene IDs I had to manually curate the Gene IDs and gene symbols. Genes which I could not confidently assign to a modern ID are not included in OncoLnc, but are still included in Table S1. Table S1 includes the original TCGA IDs and symbols along with the updated names and symbols, and Table S4 lists genes which had either the symbol or ID changed. OncoLnc allows users to search mRNAs using either an updated HUGO gene symbol or Entrez Gene ID.

miRNAs

Table 2 contains information about the patients for each Tier 3 miRNA study included in OncoLnc, and how many gene analyses are present in OncoLnc for each study. Tier 3 miRNASeq was used for every cancer except GBM, which only had microarray data available. The results of every Cox regression performed are included in Table S2. Many of the miRBase IDs, or possibly read counts, present in Table S2 and OncoLnc will be different from the IDs and read counts in TCGA data files and available at other data portals for TCGA data. This is because I went through each expression file and updated the IDs and read counts.

The "isoform.quantification" files contain both miRBase IDs as well accession numbers. In these files the 5p and 3p arms of miRNAs are referred to with the same ID, for example hsa-let-7b-5p and hsa-let-7b-3p would both be listed as hsa-let-7b. In order to update the names and read counts for the Tier 3 miRNAs I used the read counts assigned to each accession number to obtain reads per million miRNAs mapped for each accession number, and updated the ID with the current miRBase ID. When an accession number was not available I used the genomic coordinates provided to identify the accession number, and therefore ID. GBM names were updated using the "aliases" file from the miRBase FTP site, and if an alias could not be confidently identified the miRNA was not included in OncoLnc, but is still in Table S2.

As a result, all expression values in Table S2 and in OncoLnc are reads per million miRNA mapped for every cancer except GBM, which are microarray normalized values. The numbers of miRNAs in Table 2 differ because the miRNA may not have been in the expression files for that cancer, or may not have met the expression cutoff. An expression cutoff of a median of .5 reads per million miRNA mapped, and less than one fourth of the patients with 0 expression was used. OncoLnc allows users to search for miRNAs with either a miRBase version 21 mature accession number or ID.

lncRNAs

Table 3 contains information about the patients for each MiTranscriptome beta lncRNA analysis, along with how many lncRNAs are included in OncoLnc for each cancer. Normalized lncRNA

counts were downloaded from <http://mitranscriptome.org/>, and these were mapped to patient barcodes using the library information provided. MiTranscriptome beta contains over 8,000 of the most differentially expressed lncRNAs in the entire MiTranscriptome dataset, but the actual number of lncRNAs in OncoLnc for each cancer is far fewer due to the expression cutoff used: a median of .1 normalized counts, and less than a fourth of patients with 0 expression. Table S3 contains every lncRNA Cox regression performed, and these are all included in OncoLnc. OncoLnc allows users to search for MiTranscriptome beta lncRNAs using either a name or transcript ID.

Discussion

Depending on the researcher, OncoLnc should be used in different ways. If a researcher is studying a specific gene and looking for a cancer association, they should go to <http://www.oncolnc.org> and perform a search with their gene of interest. Instead of focusing on p-values, I would focus more on the rank of the correlations for the different cancers, and also on the sign of the Cox coefficients. A positive Cox coefficient indicates high expression of the gene increases the risk of death, while a negative Cox coefficient indicates the opposite. A gene with a high rank in multiple cancers (indicated by a low number, 1 being the best), and Cox coefficients with the same sign could be very interesting. It is also important to look at the level of expression of the gene. Different genes obviously require different levels of expression to exert their effects, but genes with expression near 0 should be dealt with caution. In addition, users can investigate the range of expression of the gene at the Kaplan-Meier plotting page. Genes that have large fold increases from the low expression to high expression group could be interesting candidates.

A researcher studying a specific cancer should download Tables S1, S2, and S3 to see which mRNAs, miRNAs, and lncRNAs are most correlated to survival for their cancer. Once they identify some genes of interest they can go to <http://www.oncolnc.org> to perform further analyses such as checking the range of expression of the gene, or if it is associated with survival in other cancers. Similarly, bioinformaticians looking to perform large scale analyses of prognostic genes can use these tables as a starting point, or if a user wants to change the Cox models they can use the GitHub code to alter the models.

The importance of the ability to perform survival correlations with lncRNAs must be emphasized. There are multiple techniques for identifying protein coding genes that are involved in cancer because mutations that occur in protein coding genes can result in missense mutations, and methods have been developed for identifying which of these mutations are drivers as opposed to simply passengers (Carter et al. 2009; Kaminker et al. 2007; Youn & Simon 2011). In contrast, because it is unclear how mutations will affect lncRNA function, methods to identify lncRNAs involved in cancer must rely on lncRNA expression. As a result, OncoLnc is one of the few resources available for finding lncRNAs involved in cancer, and if a lncRNA researcher is searching for a novel lncRNA to study, Table S3 would be a good place to start.

When using OncoLnc it important to remember that the correlations observed, regardless of p-value, are still only correlations. Perhaps the largest limitation of OncoLnc is that the Cox models do not account for intra-cancer subtypes. For example, GBM and BRCA both have well-established subtypes (Brennan et al. 2013; Perou et al. 2000). If the expression of a gene correlates with cancer subtypes, and those subtypes correlate with survival, subtype would be a confounding variable. As subtype definitions for the different cancers improve a future version of OncoLnc may be able to incorporate the subtypes in the Cox models.

An analysis is only as good as the data available, and the Tier 3 TCGA RNA-SEQ analyses were performed with outdated software and transcript information. There have been some attempts to reanalyze both the TCGA mRNA RNA-SEQ data and miRNA-SEQ data (Kuo et al. 2015; Rahman et al. 2015). In the event that TCGA or the scientific community releases a gold standard analysis of TCGA data, a future version of OncoLnc could incorporate this data.

Current data portals for TCGA data only allow users to view the results for one cancer at a time, may or may not offer Cox regression results, do not allow for complete control over separating patients during Kaplan-Meier analysis, and do not allow for download of the data used in the analysis. To my knowledge OncoLnc is the only online resource for TCGA data that includes these features, is the only resource that uses modern gene definitions for TCGA mRNA and miRNA data, and is the only resource for survival analysis of MiTranscriptome beta lncRNAs. In addition, current methods for survival analysis rely on a p-value cutoff of .05 for significance, which may lead to either the study of genes not actually correlated with survival or missing genes that are correlated with survival depending on the cancer. By storing the results of the correlation for every gene, OncoLnc can provide a context for the significance of a correlation. As a result, used correctly OncoLnc can not only increase the sensitivity of finding genes involved in cancer, but also the specificity. This combination of ease of use, results for complex analyses, and tools for exploring and downloading data make OncoLnc an invaluable resource for cancer researchers.

Additional Information and Declarations

Competing Interests

I offer services at omnesres.com which may involve web development or analysis of TCGA data.

Author Contributions

I conceived the project, downloaded and analyzed all data, developed OncoLnc, wrote the manuscript, and maintain the GitHub repository and any associated material at omnesres.com.

Funding

This project was not funded.

Acknowledgments

This project was made possible by data generated by the TCGA Research Network:
<http://cancergenome.nih.gov/>.

References

- Anaya J, Reon B, Chen W, Bekiranov S, and Dutta A. 2016. A pan-cancer analysis of prognostic genes. *PeerJ* 3:e1499. 10.7717/peerj.1499
- Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukheim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, and Network TR. 2013. The somatic genomic landscape of glioblastoma. *Cell* 155:462-477. 10.1016/j.cell.2013.09.034
- Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, and Karchin R. 2009. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. *Cancer Res* 69:6660-6667. 10.1158/0008-5472.can-09-1133
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, and Schultz N. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2:401-404. 10.1158/2159-8290.cd-12-0095
- Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, and Sander C. 2013. Emerging landscape of oncogenic signatures across human cancers. *Nat Genet* 45:1127-1133. 10.1038/ng.2762
- Gyorffy B, Surowiak P, Budczies J, and Lanczky A. 2013. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. *PLoS One* 8:e82241. 10.1371/journal.pone.0082241
- Han L, Yuan Y, Zheng S, Yang Y, Li J, Edgerton ME, Diao L, Xu Y, Verhaak RG, and Liang H. 2014. The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. *Nat Commun* 5:3963. 10.1038/ncomms4963
- Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Cancer Genome Atlas Research N, Benz CC, Perou CM, and Stuart JM. 2014. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell* 158:929-944. 10.1016/j.cell.2014.06.049
- Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, and Chinnaiyan AM. 2015. The landscape of long noncoding RNAs in the human transcriptome. *Nat Genet* 47:199-208. 10.1038/ng.3192
- Kaminker JS, Zhang Y, Watanabe C, and Zhang Z. 2007. CanPredict: a computational tool for predicting cancer-associated missense mutations. *Nucleic Acids Res* 35:W595-598. 10.1093/nar/gkm405
- Koch A, De Meyer T, Jeschke J, and Van Criekinge W. 2015. MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data. *BMC Genomics* 16:636. 10.1186/s12864-015-1847-z

- 285 Kuo WT, Su MW, Lee YL, Chen CH, Wu CW, Fang WL, Huang KH, and Lin WC. 2015. Bioinformatic
286 Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets. *J Clin Med*
287 4:1798-1814. 10.3390/jcm4091798
- 288 Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, Weinstein JN, and Liang H. 2015. TANRIC: An Interactive
289 Open Platform to Explore the Function of lncRNAs in Cancer. *Cancer Res* 75:3728-3737.
290 10.1158/0008-5472.can-15-0273
- 291 Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen
292 LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO,
293 and Botstein D. 2000. Molecular portraits of human breast tumours. *Nature* 406:747-752.
294 10.1038/35021093
- 295 Rahman M, Jackson LK, Johnson WE, Li DY, Bild AH, and Piccolo SR. 2015. Alternative preprocessing of
296 RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results.
297 *Bioinformatics* 31:3666-3672. 10.1093/bioinformatics/btv377
- 298 Yang Y, Han L, Yuan Y, Li J, Hei N, and Liang H. 2014. Gene co-expression network analysis reveals
299 common system-level properties of prognostic genes across cancer types. *Nat Commun* 5:3231.
300 10.1038/ncomms4231
- 301 Yarmishyn AA, and Kurochkin IV. 2015. Long noncoding RNAs: a potential novel class of cancer
302 biomarkers. *Front Genet* 6:145. 10.3389/fgene.2015.00145
- 303 Youn A, and Simon R. 2011. Identifying cancer driver genes in tumor genome sequencing studies.
304 *Bioinformatics* 27:175-181. 10.1093/bioinformatics/btq630

305

Table 1(on next page)

Characteristics of the Tier 3 mRNA datasets in OncoLnc

Age at diagnosis is in years, and is an average. The events indicate the number of deaths in the dataset. Median survival is in days and could not be calculated for COAD, KIRP, OV, READ, and UCEC.

Cancer	Patients	Male/Female	Age at Diagnosis	Events	Median Survival	Genes in OncoLnc
BLCA	403	296/107	68.03	177	1008	16339
BRCA	1006	11/995	58.34	135	3941	16602
CESC	264	0/264	48.23	59	4086	16330
COAD	440	235/205	66.58	85	NA	16378
ESCA	144	126/18	60.51	59	801	16790
GBM	152	99/53	59.84	27	1426	16783
HNSC	497	364/133	61.24	207	1732	16614
KIRC	523	341/182	60.56	167	2764	16638
KIRP	285	210/75	61.45	44	NA	16399
LAML	151	81/70	54.40	92	577	15227
LGG	510	282/228	43.02	124	2835	16781
LIHC	360	244/116	59.41	126	1694	15824
LUAD	492	225/267	65.32	176	1492	16748
LUSC	489	362/127	67.23	169	2224	16942
OV	294	0/294	59.19	42	NA	16893
PAAD	175	96/79	64.37	92	607	17177
READ	159	88/71	64.58	22	NA	16472
SARC	259	118/141	60.71	98	1991	16197
SKCM	459	284/175	58.14	215	2454	16030
STAD	379	247/132	65.49	146	1043	16885
UCEC	541	0/541	63.95	90	NA	16670

Table 2 (on next page)

Characteristics of the Tier 3 miRNA datasets in OncoLnc

Age at diagnosis is in years, and is an average. The events indicate the number of deaths in the dataset. Median survival is in days and could not be calculated for COAD, KIRP, READ, and UCEC.

Cancer	Patients	Male/Female	Age at Diagnosis	Events	Median Survival	Genes in OncoLnc
BLCA	404	297/107	68.02	177	1036	512
BRCA	988	11/977	58.35	131	3941	479
CESC	267	0/267	48.27	59	4086	501
COAD	426	226/200	66.48	84	NA	476
ESCA	144	125/19	60.61	59	801	494
GBM	561	343/218	57.94	67	2648	507
HNSC	501	363/138	61.30	208	1732	514
KIRC	506	331/175	60.48	165	2764	448
KIRP	286	210/76	61.52	44	NA	430
LAML	164	88/76	54.05	100	518	374
LGG	506	278/228	43.07	123	2660	486
LIHC	362	248/114	59.41	125	1791	485
LUAD	490	226/264	65.35	175	1492	493
LUSC	467	346/121	67.43	160	2224	519
OV	470	0/470	59.85	92	3128	467
PAAD	175	96/79	64.37	92	607	494
READ	154	84/70	64.23	22	NA	495
SARC	259	119/140	60.85	98	1991	455
SKCM	438	271/167	58.01	207	2470	535
STAD	400	260/140	65.54	155	1043	495
UCEC	534	0/534	63.91	87	NA	518

Table 3(on next page)

Characteristics of the MiTranscriptome beta analyses in OncoLnc

Age at diagnosis is in years, and is an average. The events indicate the number of deaths in the dataset. Median survival is in days and could not be calculated for COAD, KIRP, and UCEC.

Cancer	Patients	Male/Female	Age at Diagnosis	Events	Median Survival	Genes in OncoLnc
BLCA	120	86/34	67.37	61	706	4322
BRCA	766	8/758	58.03	111	3941	4708
CESC	106	0/106	48.22	26	3046	4493
COAD	117	52/65	69.64	24	NA	3302
GBM	144	94/50	59.56	24	1426	4524
HNSC	288	211/77	61.40	133	1762	4314
KIRC	457	299/158	60.75	156	2764	5191
KIRP	73	51/22	59.78	17	NA	4627
LAML	20	15/5	54.75	10	580	3940
LGG	217	123/94	42.82	65	2660	4875
LIHC	65	40/25	60.97	41	1005	3610
LUAD	320	148/172	65.72	118	1357	4636
LUSC	330	244/86	67.16	112	2284	4979
OV	369	0/369	59.63	69	3128	4901
READ	42	22/20	66.67	8	1581	3310
SKCM	255	159/96	56.82	148	2192	3893
STAD	148	93/55	65.72	56	940	4619
UCEC	274	0/274	63.12	39	NA	3706

1

Example of OncoLnc search results

The Cox coefficient and p-value are from the gene term in precomputed multivariate Cox regressions. The FDR correction is performed per cancer analysis per data type, and in this example the correction would have involved around 16,000 genes for each cancer. The rank is also performed per cancer per data type. In this example DONSON is the 3rd most highly correlated gene in KIRC.

Cox regression results for DONSON

Cancer ⁱ	Cox Coefficient	P-Value	FDR Corrected	Rank ⁱ	Median Expression ⁱ	Mean Expression	Plot Kaplan?
BLCA	-0.005	9.50e-01	9.79e-01	15844	410.38	478.94	Yes Please!
BRCA	0.192	2.80e-02	3.08e-01	1494	268.08	341.28	Yes Please!
CESC	-0.152	2.50e-01	5.95e-01	6770	665.25	681.12	Yes Please!
COAD	-0.123	2.40e-01	5.44e-01	7106	279.33	296.04	Yes Please!
ESCA	-0.123	3.60e-01	9.77e-01	6053	334.31	379.24	Yes Please!
GBM	-0.224	3.20e-01	9.62e-01	5406	352.85	389.29	Yes Please!
HNSC	0.009	9.00e-01	9.64e-01	15462	275.38	330.77	Yes Please!
KIRC	0.574	8.00e-12	4.45e-08	3	148.77	169.63	Yes Please!
KIRP	0.588	9.90e-05	1.98e-03	813	187.15	209.66	Yes Please!
LAML	0.234	5.50e-02	4.05e-01	2051	381.27	401.45	Yes Please!
LGG	0.333	4.10e-04	1.60e-03	4308	203.47	230.77	Yes Please!
LIHC	0.188	5.50e-02	2.32e-01	3738	300.81	354.61	Yes Please!
LUAD	0.159	2.30e-02	1.29e-01	2946	253.81	295.14	Yes Please!
LUSC	-0.09	2.40e-01	8.35e-01	4762	329.73	380.92	Yes Please!
OV	-0.028	8.50e-01	9.92e-01	14385	253.27	303.44	Yes Please!
PAAD	0.05	6.40e-01	7.93e-01	13828	187.31	196.42	Yes Please!
READ	-0.168	4.30e-01	9.24e-01	7545	269.13	278.58	Yes Please!
SARC	0.255	2.20e-02	1.54e-01	2273	391.13	470.87	Yes Please!
SKCM	0.146	3.80e-02	1.51e-01	3999	348.03	375.7	Yes Please!
STAD	-0.059	4.90e-01	8.02e-01	10245	304.86	327.4	Yes Please!
UCEC	0.009	9.30e-01	9.95e-01	15404	278.83	315.72	Yes Please!

2

Example of OncoLnc Kaplan-Meier results

A) Submitting non-overlapping percentiles will return a logrank p-value for the analysis and a PNG image with the option to generate a PDF of the plot.B) Below the Kaplan-Meier image will be the data that was plotted along with an option to download a csv file.

a

Kaplan plot for DONSON in KIRC

25


25

Submit



If you make multiple plots be sure to reload the page to ensure an updated image!

Go to PDF



b

For an excel file of this data

Click Here

Low Group

Patient	Days	Status	Expression
TCGA-B0-5702	2172	Alive	15.78
TCGA-AK-3447	1217	Alive	37.58
TCGA-B0-5117	1608	Alive	44.0
TCGA-A3-3374	1314	Alive	47.14
TCGA-B0-4834	2090	Dead	47.37
TCGA-AK-3453	2531	Alive	47.92
TCGA-B2-5636	919	Alive	50.59
TCGA-B0-5083	1045	Dead	50.85
TCGA-CW-5587	2226	Alive	51.64
TCGA-BP-4177	1670	Alive	54.22
TCGA-B8-5553	435	Alive	54.85
TCGA-B8-4619	523	Alive	55.0
TCGA-B0-5402	1290	Alive	55.77
TCGA-AK-3428	3728	Alive	56.53
TCGA-AK-3440	2865	Alive	56.99
TCGA-B0-5695	2150	Alive	60.74
TCGA-BP-4801	1124	Alive	60.78
TCGA-CW-5585	2609	Alive	61.84
TCGA-B2-3923	992	Alive	62.04
TCGA-BP-4994	1308	Alive	62.19
TCGA-CZ-5451	1929	Alive	63.53
TCGA-BP-5168	1463	Dead	63.89
TCGA-BP-5192	714	Alive	63.99
TCGA-CW-5583	2489	Alive	64.31
TCGA-CJ-4885	3451	Alive	64.64
TCGA-B0-5705	4537	Alive	65.52
TCGA-AK-3450	1779	Alive	65.86

High Group

Patient	Days	Status	Expression
TCGA-B8-5163	822	Alive	205.01
TCGA-CJ-4641	1661	Dead	205.13
TCGA-B0-5116	1274	Alive	205.5
TCGA-BP-5010	878	Dead	205.98
TCGA-B8-A546	53	Alive	206.17
TCGA-BP-4981	1097	Dead	206.24
TCGA-CW-6087	41	Dead	206.47
TCGA-BP-4986	785	Alive	206.54
TCGA-BP-4771	162	Dead	207.08
TCGA-A3-3382	574	Alive	207.49
TCGA-BP-4774	1885	Alive	207.69
TCGA-CW-6097	571	Dead	208.62
TCGA-CZ-4862	3271	Alive	208.64
TCGA-B0-5081	362	Dead	208.65
TCGA-CJ-4888	1567	Dead	208.69
TCGA-CZ-5989	1905	Alive	209.11
TCGA-B0-5094	333	Dead	209.96
TCGA-B0-4836	1238	Dead	212.42
TCGA-CJ-4640	3480	Alive	212.94
TCGA-B0-4706	65	Dead	214.73
TCGA-A3-3380	567	Alive	215.69
TCGA-CZ-4861	446	Dead	216.26
TCGA-B0-5102	2764	Dead	216.52
TCGA-A3-3322	1478	Alive	217.26
TCGA-A3-3325	1170	Dead	218.45
TCGA-BP-4989	118	Alive	219.2
TCGA-BP-4346	1493	Dead	219.38